Sequenom Buys Small Diagnostic Maker

Sequenom, the San Diego-based developer of a non-invasive prenatal test for Down Syndrome, said today it has acquired Ann Arbor, MI-based SensiGen for $8.7 million, plus potential milestones. The deal gives Sequenom (NASDAQ: SQNM) molecular diagnostics for human papillomavirus, lupus, chronic kidney disease, and inflammatory bowel disease. The purchase is part of Sequenom’s strategy to offer diagnostics for women’s health and cancer, CEO Harry Stylli said in a statement.

Trending on Xconomy